相关实验视频

Updated: Jun 17, 2026

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics

Published on: May 11, 2016

高ALDH-1表达预测放射治疗的不完全反应在第三阶段状细胞宫癌患者患者

Moh Nailul Fahmi^1,2, Fitriyadi Kusuma³, Tantri Hellyanti⁴

¹Fellowship Gynecology Oncology Division, Department of Obstetrics and Gynecology, Universitas Indonesia, Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine, Jakarta, Indonesia.

Asian Pacific journal of cancer prevention : APJCP

|June 28, 2023

概括

高化脱酶1 (ALDH1) 表达与宫癌III期放射治疗反应不佳有关. 这一发现可能有助于预测患有状细胞宫癌的患者的治疗结果.

科学领域:

在瘤学瘤学.
生物化学生物化学
放射治疗研究放射治疗研究

背景情况:

甲基脱酶1 (ALDH1) 被确定为宫癌干细胞的标记物.
ALDH1表现出放射电阻,有助于解决治疗挑战.
放射治疗后的复发和转移仍然是宫癌患者的重要问题.

研究的目的:

为了研究ALDH1表达和放射治疗反应之间的相关性.
评估ALDH1作为第三阶段状细胞宫癌 (SCCC) 的预测标志物.

主要方法:

对58名第三阶段SCCC患者的回顾性分析,这些患者接受了外部光束辐射和支臂疗法.
在宫组织活检上使用免疫组织化学评估治疗前的ALDH1表达.
使用SPSS 24的完全响应者和不完全响应者之间的ALDH1分数的比较.

主要成果:

通过ROC曲线分析 (AUC 0.682) 确定了166.05 pg/mL的ALDH1得分截止值.
ALDH1表达≥166.05 pg/mL显著增加了不完全反应的风险 (adj OR 3.127,p=0.043).
瘤大小,分化,脏异常和角质化与辐射反应无关.

结论:

升高的ALDH1表达与第三阶段SCCC放射治疗的不完全反应有关.
在宫癌中,ALDH1可以作为放射治疗结果的预测生物标志物.

关键词:

一个名为ALDH-1的.关键词: 状细胞宫癌辐射的完整反应.免疫组织化学免疫组织化学

更多相关视频

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors

Published on: March 1, 2020

Application of AlDeSense to Stratify Ovarian Cancer Cells Based on Aldehyde Dehydrogenase 1A1 Activity

Application of AlDeSense to Stratify Ovarian Cancer Cells Based on Aldehyde Dehydrogenase 1A1 Activity

Published on: March 31, 2023

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...